Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 + irinotecan in recurrent/metastatic esophageal squamous cell carcinoma
NCT05022654Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Dec 2021; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05022654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022654.